Navigation

Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib (review)

Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours (part review of TA86)

Status: History
Expected date of issue: November 2010
Process: MTA
Topic area:
  • Cancer
  • Digestive system
 

NICE project team

Executive Lead: Peter Littlejohns
Technical Lead: Joao Vieira
Communications manager: Alice Law
Project manager: Jeremy Powell
Assessment Group / Evidence Review Group: Aberdeen Health Technology Assessment Group
Top


 

Provisional schedule

Consultation on draft scope by stakeholders: 25 June 2009
Closing date for invited submissions / evidence submission: 23 November 2009
1st appraisal committee meeting: 02 June 2010
2nd appraisal committee meeting: 04 August 2010
Top


 

Consultees and commentators

Consultees

Commentators (no right to submit or appeal)

Manufacturers/sponsors

  • Novartis (imatinib)

Patient/carer groups

  • Beating Bowel Cancer
  • Bowel Cancer UK
  • GIST Support UK
  • Macmillan Cancer Support
  • Rarer Cancers Forum
  • Sarcoma UK

Professional groups

  • Cancer Research UK
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians, Medical Oncology Joint Special Committee
  • United Kingdom Oncology Nursing Society

Others

  • Department of Health
  • Welsh Assembly Government

General

  • Department of Health, Social Services and Public Safety for Northern Ireland
  • NHS Quality Improvement Scotland

Comparator manufacturer(s)

  • Pfizer (sunitinib)

Relevant research groups

  • National Cancer Research Institute

Assessment Group

  • Aberdeen Health Technology Assessment Group
  • National Institute for Health Research Health Technology Assessment Programme

Associated Guideline Groups

  • National Collaborating Centre for Cancer

Top


 

Key documents

This page was last updated: 21 February 2011

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.